Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.41 |
| ▸ | FNTB | P49356 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13461665 | 0.85 | CYP17A1 (0.43) | LMNASMN1; SMN2IDO1TDO2CYP3A4 | |
| SCHEMBL7571137 | 0.84 | KDM4E (0.49) | LMNASMN1; SMN2IDO1TDO2CYP3A4 | |
| SCHEMBL4395448 | 0.83 | IDO1 (0.42) | LMNASMN1; SMN2IDO1TDO2FNTA | |
| SCHEMBL16462470 | 0.83 | CYP3A4 (0.41) | LMNASMN1; SMN2IDO1TDO2CYP3A4 | |
| SCHEMBL5099434 | 0.80 | FNTA (0.50) | FNTAFNTBPGGT1B | |
| SCHEMBL5094152 | 0.76 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL16460462 | 0.75 | SMN1; SMN2 (0.59) | LMNASMN1; SMN2IDO1TDO2ALDH1A1 | |
| SCHEMBL3530021 | 0.74 | LMNA (0.55) | HRH3LMNASMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL16460574 | 0.73 | HRH3 (0.43) | HRH3LMNASMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL7569001 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2814814-B1 | IMIDAZOLYLKETONE DERIVATIVES ASD ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| EP-2814814-B1 | IMIDAZOLYLKETONE DERIVATIVES ASD ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-9464058-B2 | Imidazolylketone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464058-B2 | Imidazolylketone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464058-B2 | Imidazolylketone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-10-11 | — | — | US | disclosed |
| EP-3057951-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015057205-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| EP-2814814-A1 | IMIDAZOLYLKETONE DERIVATIVES ASD ALDOSTERONE SYNTHASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-20140128429-A1 | NEW IMIDAZOLYLKETONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128429-A1 | NEW IMIDAZOLYLKETONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128429-A1 | NEW IMIDAZOLYLKETONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2014-05-08 | — | — | US | disclosed |
| WO-2013120771-A1 | IMIDAZOLYLKETONE DERIVATIVES ASD ALDOSTERONE SYNTHASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013120771-A1 | IMIDAZOLYLKETONE DERIVATIVES ASD ALDOSTERONE SYNTHASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-7323570-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2008-01-29 | — | — | US | disclosed |
| US-7211595-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | ABBVIE INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1339695-B1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20030087940-A1 | Farnesyltransferase inhibitors | ABBVIE INC. | 2003-05-08 | — | — | US | disclosed |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | FNTB, FNTA, ACAT2 | HRH3 4532/4885LMNA 1756/4885SMN1; SMN2 4259/4885 |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | FNTB, FNTA, FDPS | HRH3 4190/4885LMNA 3187/4885SMN1; SMN2 4698/4885 |
| US-20030087940-A1 | Farnesyltransferase inhibitors | FNTB, FNTA, FDPS | HRH3 4297/4885LMNA 3363/4885SMN1; SMN2 4626/4885 |
| US-20140128429-A1 | NEW IMIDAZOLYLKETONE DERIVATIVES | KCNK4, NEK5, FN3KRP | HRH3 1902/4885LMNA 1477/4885SMN1; SMN2 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.